Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Annovis Bio Inc
(NY:
ANVS
)
10.06
+0.21 (+2.13%)
Official Closing Price
Updated: 7:00 PM EDT, Apr 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Annovis Bio Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
April 02, 2024
From
Annovis Bio Inc.
Via
GlobeNewswire
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
December 04, 2023
No matter which holiday you're planning gifts for, Christmas, Hanukkah, or some other occasion, there may be one great gift idea you haven't thought of yet.
Via
MarketBeat
Topics
Bonds
Exposures
Debt Markets
Annovis Bio Measures Novel Biomarkers in Plasma of Parkinson’s Patients
November 02, 2023
From
Annovis Bio
Via
Business Wire
Annovis Bio Announces Pricing of $7.5 Million Public Offering
October 31, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Annovis Bio Announces Launch of Proposed Public Offering
October 30, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer’s Disease Patients From the Independent Data and Safety Monitoring Board (DSMB)
October 30, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference
October 24, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Annovis Bio Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 15, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Continued Positive Performance of Novel Drug Development by Annovis Bio Presented at 2023 Alzheimer's Association International Conference
July 18, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Annovis Bio Announces the Filing of a Groundbreaking Patent
June 27, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Annovis Bio Receives Excellent Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson’s Disease Patients from the Independent Data and Safety Monitoring Board (DSMB)
June 20, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update
May 04, 2022
Berwyn, Pennsylvania--(Newsfile Corp. - May 4, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...
Via
Newsfile
Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging
April 28, 2022
Berwyn, Pennsylvania--(Newsfile Corp. - April 28, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...
Via
Newsfile
Annovis Bio to Participate in World Parkinson's Day to Raise Awareness on the Debilitating Disease
April 11, 2022
Berwyn, Pennsylvania--(Newsfile Corp. - April 11, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...
Via
Newsfile
Annovis Bio to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
March 23, 2022
Berwyn, Pennsylvania--(Newsfile Corp. - March 23, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...
Via
Newsfile
Annovis Bio Presents at International Conference on Alzheimer's & Parkinson (AD/PD 2022)
March 18, 2022
Berwyn, Pennsylvania--(Newsfile Corp. - March 18, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...
Via
Newsfile
Annovis Bio Announces Presentation at International Conference on Alzheimer's & Parkinson's Diseases 2022
March 08, 2022
Berwyn, Pennsylvania--(Newsfile Corp. - March 8, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...
Via
Newsfile
Annovis Bio to Present at the Cowen 42nd Annual Health Care Conference
March 03, 2022
Berwyn, Pennsylvania--(Newsfile Corp. - March 3, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...
Via
Newsfile
Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease
January 25, 2022
Berwyn, Pennsylvania--(Newsfile Corp. - January 25, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...
Via
Newsfile
Exposures
Product Safety
Annovis Bio Enhances Leadership Team with Two Senior Appointments
January 10, 2022
Company Appoints Eve Damiano, MS, RAC, as Senior Vice President of Regulatory OperationsCompany Promotes Cheng Fang, Ph.D., to Senior Vice...
Via
Newsfile
Annovis Bio Announces Official Unique Name Buntanetap for Lead Candidate ANVS401
January 05, 2022
Berwyn, Pennsylvania--(Newsfile Corp. - January 5, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...
Via
Newsfile
Annovis Bio to Participate in the Biotech Showcase and H.C. Wainwright Bioconnect Virtual Conferences
January 03, 2022
Berwyn, Pennsylvania--(Newsfile Corp. - January 3, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...
Via
Newsfile
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
December 20, 2021
Berwyn, Pennsylvania--(Newsfile Corp. - December 20, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage...
Via
Newsfile
Annovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics
December 14, 2021
Berwyn, Pennsylvania--(Newsfile Corp. - December 14, 2021) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...
Via
Newsfile
Annovis Bio Presented At The 14th Clinical Trials on Alzheimer's Disease Conference
November 12, 2021
Berwyn, Pennsylvania--(Newsfile Corp. - November 12, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage...
Via
Newsfile
Exposures
Product Safety
Annovis Bio Presents Poster on Mechanism of Action at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference
November 09, 2021
Berwyn, Pennsylvania--(Newsfile Corp. - November 9, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage...
Via
Newsfile
SHAREHOLDER ALERT: Robbins LLP Investigates Annovis Bio, Inc. (ANVS) for Misleading Shareholders
November 03, 2021
From
Robbins LLP
Via
Business Wire
Annovis Bio to Present at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference
November 02, 2021
Dr. Maria Maccecchini will present additional Phase 2 data on November 12, 10:25 a.m. ESTA poster highlighting the mechanism of...
Via
Newsfile
MONDAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Annovis Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
October 16, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
ANNOVIS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Annovis Bio, Inc. and Encourages Investors to Contact the Firm
October 15, 2021
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.